All News

Just think what Frankenstein could do with this product. It looks like skin, feels like skin, but it’s not skin. It’s LabSkin, a facsimile, being manufactured by a clinical research group Venn Life Sciences.

A milestone of sorts took place on Monday March 3 when MarijuanaDoctors.com began airing a television commercial that looks to be the first ever marijuana commercial on a major TV network.

Despite recent legislation to establish a more secure pharmaceutical supply chain to deliver high quality, approved medicines to American patients, efforts to block the import of substandard, fraudulent, and counterfeit drugs remains an uphill fight.

Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered. A revolution in the making, where legislation combined with market forces as well as community and stakeholder advocacy are adding fresh momentum to a population-based approach to health practice. Population health focuses on a system built around three pillars of care: preventive care, primary care, and coordinated care, all driven by a single performance metric, which is value, as evidenced through quality and outcomes. Executing around this integrative model depends entirely on partnerships, especially with non-traditional players like the physician assistant.

Widespread screening, along with new therapies that move patients from a chronic condition to a cure, is changing the landscape in treatment of hepatitis C, says an expert panel recently convened by the American Journal of Managed Care (AJMC).

The Myelin Repair Foundation is more than just a policy precedent - it’s also emerging as the stimulus behind a future cure for MS.

While biosimilar products have been launched in Asia and Europe, they are at least three years away in the US, according to a new report on the global biosimilar drugs market.

When the Generic Drug User Fee Act (GDUFA) was signed into law on July 7, 2012, its primary intent was to provide FDA with the additional resources necessary to expedite the review process for generic drugs, and combat the agency’s backlog of drug applications.

Swedish Orphan Biovitrum AB (Sobi) was last night presented with a EURORDIS Award for its commercial and development portfolio in the field of rare diseases.

Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.

Not long ago, I was privy to a discussion taking place in a large drug development services company.

Following the U.S. ban on all imports from Ranbaxy’s Toansa, India, facility, the drug maker has voluntarily suspended all shipments of bulk drugs from its manufacturing facilities both at Toansa and Dewas, in order to reassess quality controls at the plants.

The latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.

In less than a decade, online video marketing has moved from a standing start to become an essential part of the digital marketing mix

This week (February 28), Europe will celebrate Rare Disease Day. This is an interesting example – one might almost say a rare example – of a successful attempt by a European interest group to capture public attention.

Any pricing or revenue management initiative is only as good as the information on which it is based.

Europe’s main pharma industry bodies - EFPIA, EGA, EuropaBio, AESGP and EUCOPE - have issued a joint statement to express concern about “the increasing financial burden of regulatory costs incurred since the adoption of the pharmacovigilance package in 2010?.

In this short video, Brianna Cayo-Cotter, Change.org’s managing director of communications, talks to Pharm Exec about how advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy, all fueled by the hour-to-hour passion of living with a disease.

Four class representatives have been added to a class-action gender-discrimination employment suit originally filed last May against Merck & Co. in New Jersey.

Cuts in healthcare costs due to post-recession austerity programs mean favorable Health Technology Assessments (HTAs) are becoming crucial to the successful market launch of pharmaceuticals in Europe.

I did something today that I haven’t done in years: I checked out the US pharmaceutical R&D spend versus the rest of the world. Having known since the 80’s that the US owned this space, a quick look at the latest R&D figures confirmed my decades old understanding of the industry’s worldwide position.

Actavis and Forest Laboratories have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest share, Actavis announced in a press release.

America’s biopharmaceutical research companies are currently developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide.

To mark its 25th year in recognizing female leadership in the tough competitive ranks of biopharma, the Healthcare Businesswomen’s Association (HBA) is opting for a breakout triple play.

Despite notable successes in preventing and mitigating short supplies of important medicines, the drug shortage crisis still disrupts medical treatment and gives drug manufacturers a bad name.

The Affordable Care Act (ACA) has sent biopharmaceutical companies scrambling to understand how their business model, including its ability to innovate, will change as healthcare reform moves forward.

As the United Kingdom debate about whether to stay in the European Union becomes more bitter and intense, an insight into how EU membership impacts on medicines and pharmaceuticals has appeared from a British politician who was until recently the UK Government Adviser on Life Sciences, George Freeman.

Accenture has launched the latest version of its annual study of the biopharmaceutical industry.

Thirty-five out of every 100 job applicants in the pharmaceutical or clinical trial space in India “are lying about their credentials”, says a report by Delhi-based employee screening firm AuthBridge.

Pleas for compassionate use access are on the increase, and Change.org is giving patients an audience.